Navigation Links
Pharmion Corporation Announces 2007 Operating Results
Date:2/19/2008

rm Act of 1995: This release contains forward-looking statements, which express the current beliefs and expectations of management. Such statements are based on current expectations and involve a number of known and unknown risks and uncertainties that could cause Pharmion's future results, performance or achievements to differ significantly from the results, performance or achievements expressed or implied by such forward-looking statements. Important factors that could cause or contribute to such differences include the outcome of ongoing clinical trials, the status and timing or regulatory approvals for Pharmion's product candidates; the impact of competition from other products under development by Pharmion's competitors; the regulatory environment and changes in the health policies and structure of various countries; uncertainties regarding market acceptance of products newly launched, currently being sold or in development; Pharmion's ability to successfully acquire rights to, develop and commercialize additional pharmaceutical products; failure of third-party manufacturers to produce the product volumes required on a timely basis, fluctuations in currency exchange rates, and other factors that are discussed in Pharmion's filings with the U.S. Securities and Exchange Commission, including those discussed in the "Risk Factors" section of Pharmion's Quarterly Reports on Form 10-Q and Annual Reports on Form 10-K. Forward-looking statements speak only as of the date on which they are made, and Pharmion undertakes no obligation to update publicly or revise any forward-looking statement, whether as a result of new information, future developments or otherwise.

PHARMION CORPORATION

CONSOLIDATED FINANCIAL RESULTS

(In thousands, except for per share amounts)

Unaudited

Three Months Ended Twelve Months Ended<
'/>"/>

SOURCE Pharmion Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Pharmion Corporation to Announce Third Quarter 2007 Financial Results
2. Pharmion and MethylGene Announce Orphan Drug Designation Granted by the European Medicines Agency (EMEA) for MGCD0103 for the Treatment of Hodgkins Lymphoma
3. Pharmion Corporation to Present at Bear Stearns 2007 Healthcare Conference
4. Pharmions Oral Azacitidine Granted Fast Track Status for Myelodysplastic Syndromes
5. Pharmion and MethylGene Announce Collaboration to Develop Sirtuin Inhibitors as Anti-Cancer Agents
6. Verenium Corporation to Present at Piper Jaffray Clean Technology & Renewables Conference
7. VLST Corporation Announces Board and Executive Management Appointments
8. AGA Medical Corporation Receives European CE Mark Approval for the AMPLATZER(R) Duct Occluder II
9. AGA Medical Corporation Responds to Occlutech Statement on the Status of the Ongoing Patent Litigation in Europe
10. LifeCell Corporation Revises Full Year 2007 Preliminary Results and Schedules Fourth Quarter 2007 Financial Results Conference Call; February 27, 2008 at 10:00 a.m. Eastern
11. Digirad Corporation Reports Financial Results for 2007 Fourth Quarter and Twelve Months
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/30/2015)... , April 30, 2015 Oxford Finance ... debt to life sciences and healthcare services companies, today ... term loan agreement with Celula, Inc., a diagnostic testing ... diseases, enabling better patient care and improved outcomes.  Proceeds ... development and expand the commercialization of its products in ...
(Date:4/30/2015)... , April 30, 2015  Asterias Biotherapeutics, Inc. ... emerging field of regenerative medicine, today announced that it ... Thursday, May 7, 2015 after the close of the ... call and webcast on Thursday, May 7, 2015 at ... the results and recent corporate developments. For ...
(Date:4/30/2015)... SureClinical, a leader in cloud-based health ... joined SureClinical’s executive team as Chief Financial Officer. ... executive with over 25 years in leadership roles ranging ... Ms. Morris joins SureClinical from Marrone Bio Innovations (MBI), ... of MBI from its founding in 2006 until 2011, ...
(Date:4/29/2015)... GUELPH, ON , April 29, 2015 /PRNewswire/ - BIOREM Inc. (TSX-V: BRM) ... twelve-month periods ended December 31, 2014. Biorem,s complete fiscal 2014 year-end financial ... FINANCIAL HIGHLIGHTS: 2014 , 2013 , 2014 ... 10,683 , 19,596 Gross profit 1,326 , ... 1,191 , 1,493 , 3,377 , ...
Breaking Biology Technology:Oxford Finance Provides $10 Million Debt Financing to Celula 2Asterias Biotherapeutics to Report First Quarter Results on May 7, 2015 2Asterias Biotherapeutics to Report First Quarter Results on May 7, 2015 3Julie I. Morris Joins SureClinical as Chief Financial Officer 2Biorem Reports Results for Fourth Quarter 2014 and Year Ended December 31, 2014 2Biorem Reports Results for Fourth Quarter 2014 and Year Ended December 31, 2014 3Biorem Reports Results for Fourth Quarter 2014 and Year Ended December 31, 2014 4
... 15 A panel of expert judges selected Nikon Instruments, ... second place among the top ten in The Scientist,s ... of invention, vision and utility. The award, the first-ever ... in the past year, acknowledges Nikon,s exclusive PFS system for ...
... Dec. 15 ADVENTRX Pharmaceuticals, Inc. (Amex: ... and commercializing proprietary product candidates primarily for the treatment ... range of strategic options, including the sale or disposition ... a strategic business merger and other transactions that maximize ...
... 15 BioMed Realty Trust, Inc.,(NYSE: BMR ) ... fourth,quarter 2008 dividend of $0.335 per share of common stock. ... common share. , BioMed ... dividend,of $0.46094 per share of the company,s 7.375% Series A ...
Cached Biology Technology:Nikon Instruments Perfect Focus System Wins Second Place in The Scientist's Top Innovations of 2008 Award 2ADVENTRX Exploring Strategic Options 2ADVENTRX Exploring Strategic Options 3ADVENTRX Exploring Strategic Options 4BioMed Realty Trust Declares Fourth Quarter 2008 Common Stock and Preferred Stock Dividends 2
(Date:3/26/2015)... The Granite Club, Canada,s ... announced it has implemented a state-of-the-art access and security ... and staff, while restricting access to authorized users only. ... IMID Access system because it has the perfect combination ... in addition to unparalleled security," said James DiRenzo ...
(Date:3/24/2015)... March 24, 2015   Crossmatch ™, a ... announced that its U.are.U ® 4500 Fingerprint ... Goorin Bros . to achieve PCI compliance for ... access to the POS terminal, protecting the retailer ... data breaches. With one-third of ...
(Date:3/23/2015)... 2015 NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" or ... mobile commerce market, announces its biometric payment technology, the Wocket® ... television starting March 30 th . ... New York markets. ... about our new ad campaign following the recent initial shipment ...
Breaking Biology News(10 mins):Granite Club First Private Club in North America to Implement FST Biometrics Secure Access Solution, as Part of Multi-million Dollar Expansion 2Crossmatch Fingerprint Readers Help Retailer Prevent Data Breaches at Point-of-Sale 2NXT-ID's Wocket Smart Wallet to Launch New CNBC Regional TV Ad Campaign 2NXT-ID's Wocket Smart Wallet to Launch New CNBC Regional TV Ad Campaign 3
... W. Finberg, MD, the Richard M. Haidack Professor of ... University of Massachusetts Medical School, is lead investigator on ... predicting how the influenza virus changes and evolves in ... This approach has promise for becoming a pivotal tool ...
... than 3,000 hybrid fish in his time as a graduate ... that has helped him create one of the most comprehensive ... key prediction in evolutionary biology. "We can see a ... new specialized species," said Martin, who with Professor Peter Wainwright ...
... crops such as miscanthus, whose high yields have led ... in producing ethanol, are now shown to have another ... in the environment. In a 4-year University of Illinois ... to typical corn-corn-soybean rotations, each of the perennial crops ...
Cached Biology News:A snapshot of pupfish evolution in action 2Lower nitrogen losses with perennial biofuel crops 2Lower nitrogen losses with perennial biofuel crops 3
Goat Anti-Horse IgG(T) Antibody, Unconjugated...
Identify and characterize Phosphoinositide (PI(3,4,5)P3) binding...
Mouse polyclonal antibody to MCFD2 - multiple coagulation factor deficiency 2...
Rabbit polyclonal to ErbB 2 (phospho Y1248) ( Abpromise for all tested applications). entrezGeneID: 2064 SwissProtID: P04626...
Biology Products: